Research

Hormonal

GLP-1-based therapies achieve clinically meaningful weight loss (exceeding 10%) in type 2 diabetes and obesity by leveraging the gut-brain axis, specifically through the activation of satiety circuits in the brainstem (area postrema and nucleus of the solitary tract).

GLP-1 medications are currently the most effective pharmacological option for significant weight loss in people with obesity or type 2 diabetes. They work by mimicking a gut hormone that signals fullness to the brain. While they are injections, they are usually taken once a week. Common side effects like nausea are often temporary and can be managed by adjusting the dose. Consult a doctor to see if this treatment is appropriate for your specific health profile.

GoodSupportsHIGH confidence
recent success with GLP-1-based injectable therapeutics and other approaches that leverage pharmacology of both GLP-1 and other gut hormones has suggested that clinically meaningful weight loss, in some cases exceeding 10%, can be safely achieved
Paul Richards et al. · Molecular Metabolism · 2021

Why this rating

The paper is a review citing multiple clinical successes and established mechanisms, though it notes some side effects (nausea).

Source

The gut–brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders

Paul Richards et al. · Molecular Metabolism · 2021

DOI 10.1016/j.molmet.2021.101175

narrative_reviewCited 78×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →